Successful Treatment of Persistent Stenotrophomonas maltophilia Bacteremia With Cefiderocol in an Infant

Alice J. Hsu*, Patricia J. Simner, Yehudit Bergman, Amy J. Mathers, Pranita D. Tamma*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Stenotrophomonas maltophilia is an important nosocomial pathogen with limited treatment options. Trimethoprim-sulfamethoxazole (TMP-SMX) is generally regarded as the preferred therapy; however, treatment failures with TMP-SMX have been reported. Herein, we report a case of a 5-week-old infant with 8 days of S. maltophilia bacteremia while receiving TMP-SMX, despite in vitro susceptibility. Transitioning to cefiderocol monotherapy resulted in blood culture clearance within 24 hours, in the absence of any additional interventions. This is the first published case of the use of cefiderocol for a pediatric patient with an infection due to S. maltophilia. We review preclinical and clinical data that underscore why cefiderocol may be an effective treatment option for S. maltophilia infections.

Original languageAmerican English
Article numberofad174
JournalOpen Forum Infectious Diseases
Volume10
Issue number4
DOIs
StatePublished - 1 Apr 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Keywords

  • aztreonam
  • ceftazidime-avibactam
  • glucose-nonfermenter
  • pediatrics
  • siderophore
  • trimethoprim-sulfamethoxazole

Fingerprint

Dive into the research topics of 'Successful Treatment of Persistent Stenotrophomonas maltophilia Bacteremia With Cefiderocol in an Infant'. Together they form a unique fingerprint.

Cite this